Drug Trial Radar · NCT05914116
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
862
Planned (sponsor's estimate)
Start
Aug 17, 2023
Primary completion
Dec 2027
Study completion May 2028
Sponsor
- Lead sponsor
- DualityBio Inc.Industry
- Sponsor type
- Industry
- Collaborators
- BioNTech SE
- First posted
- Jun 22, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Conditions
- Advanced Solid Tumors
Interventions
DB-1311Drug
Administered I.V.(intravenous infusion)
Lopinavir and Ritonavir TabletsDrug
Lopinavir and Ritonavir Tablets
itraconazoleDrug
itraconazole
EnzalutamideDrug
oral administration
AbirateroneDrug
oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Percentage of Participants with Dose-Limiting Toxicities (DLTs) as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Percentage of participants in Part 1 with DLTsTime frame: up to 21 days after Cycle 1 Day 1
- Phase 1& Phase 2a: Percentage of Participants with Treatment Emergent Adverse Events (TEAEs) as assessed by CTCAE v5.0.Time frame: Up to follow-up period, approximately 1 year post-treatment
- Phase 1& Phase 2a: Percentage of Participants with Serious Adverse Events (SAEs) as assessed by CTCAE v5.0.Time frame: Up to follow-up period, approximately 1 year post-treatment
- Phase 1 & Phase 2a: vital sign measurementsTime frame: Up to follow-up period, approximately 1 year post-treatment
- Phase 1& Phase 2a: clinical safety laboratory parametersTime frame: Up to follow-up period, approximately 1 year post-treatment
- Phase 1& Phase 2a: Electrocardiogram (ECG) parametersTime frame: Up to follow-up period, approximately 1 year post-treatment
- Phase 1& Phase 2a: Eastern Cooperative Oncology Group (ECOG) performance status (PS)Time frame: Up to follow-up period, approximately 1 year post-treatment
- Phase 1& Phase 2a: left ventricular ejection fraction (LEVF)Time frame: Up to follow-up period, approximately 1 year post-treatment
- Phase 1: Maximum Tolerated Dose (MTD) of DB-1311/BNT324Time frame: Up to the completion of Part 1 (assessed up to 12 months)
- Phase 1: Recommended Phase 2 Dose (RP2D) of DB-1311/BNT324Time frame: Up to the completion of Part 1 (assessed up to 12 months)
- Phase 2a: Objective Response Rate (ORR) as determined by investigatorTime frame: Up to follow-up period, approximately 1 year post-treatment
Locations
107 sites in 4 countries. Site status is shown where the registry gives one.
Research Site 111
Tucson, Arizona · Recruiting
Research Site 125
Los Angeles, California · Recruiting
Research Site 133
Los Angeles, California · Recruiting
Research Site 103
Los Angeles, California · Recruiting
Research Site 128
Santa Monica, California · Recruiting
Research Site 118
Celebration, Florida · Recruiting
Research Site 127
Margate, Florida · Recruiting
Research Site 137
Orlando, Florida · Recruiting
Research Site 101
Plantation, Florida · Recruiting
Research Site 109
Tamarac, Florida · Recruiting
Research Site 114
Atlanta, Georgia · Recruiting
Research Site 139
Atlanta, Georgia · Recruiting
Research Site 115
Louisville, Kentucky · Recruiting
Research Site 129
Detroit, Michigan · Recruiting
Research Site 121
Saint Paul, Minnesota · Recruiting
Research Site 110
Las Vegas, Nevada · Recruiting
Research Site 107
New York, New York · Recruiting
Research Site 138
Canton, Ohio · Recruiting
Research Site 113
Cincinnati, Ohio · Recruiting
Research Site 131
Dayton, Ohio · Recruiting
Research Site 123
Charleston, South Carolina · Recruiting
Research Site 108
Greenville, South Carolina · Recruiting
Research Site 136
Nashville, Tennessee · Recruiting
Research Site 135
Austin, Texas · Recruiting
Research Site 120
Dallas, Texas · Recruiting
Research Site 102
Fairfax, Virginia · Recruiting
Research Site 112
Fairfax, Virginia · Recruiting
Research Site 105
Spokane, Washington · Recruiting
Research Site 208
Blacktown, New South Wales, Australia · Recruiting
Research Site 215
Camperdown, New South Wales, Australia · Recruiting
Research Site 212
Concord, New South Wales, Australia · Recruiting
Research Site 217
New Lambton Heights, New South Wales, Australia · Recruiting
Research Site 201
Sydney, New South Wales, Australia · Recruiting
Research Site 205
Sydney, New South Wales, Australia · Recruiting
Research Site 206
Sydney, New South Wales, Australia · Recruiting
Research Site 216
Waratah, New South Wales, Australia · Recruiting
Research Site 209
Birtinya, Queensland, Australia · Recruiting
Research Site 203
Brisbane, Queensland, Australia · Recruiting
Research Site 210
Gold Coast, Queensland, Australia · Recruiting
Research Site 202
Nedlands, Western Australia, Australia · Recruiting
Showing 40 of 107 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.